The Effects of Juglone on Cell Proliferation and Insulin-Like Growth Factor I Receptor/Phosphoinositide 3-Kinase/p85 (IGF-IR/PI3K/p85) Signaling Pathway in Pancreatic Cancer.
Dursunoğlu. Duygu D; Arikoğlu. Hilal H; Kaya. Dudu Erkoç DE; Göktürk. Fatma F
Key Findings
- Juglone reduced IGF‑1 receptor (IGF‑IR) protein levels in PANC‑1 cancer cells
- Juglone lowered PCNA, a marker of cell proliferation
- Juglone decreased transcription of p85/PIK3R1, a downstream part of the IGF‑IR/PI3K pathway
Practical Outcomes
- The study shows juglone can block IGF‑1 signaling in pancreatic cancer cells, but it was done in vitro and the compound is known to be toxic. There’s no safe, evidence‑based way for biohackers to use juglone for longevity or performance, and it should not be tried without medical supervision.
Summary
Researchers tested a plant compound called juglone on pancreatic cancer cells and found it lowered the levels of the IGF‑1 receptor and other markers that tell cells to grow, which slowed the cancer cells' growth in a lab dish. This effect was seen at micromolar concentrations after 24 hours.
Abstract
Pancreatic adenocarcinoma is a highly aggressive cancer with a poor prognosis, a high potential for invasion and metastasis, and resistance to therapy. We have previously demonstrated the cytotoxic, apoptotic, and antimetastatic effects of juglone. The insulin-like growth factor I receptor/phosphoinositide 3-kinase (IGF-IR/PI3K) signaling pathway plays an important role in tumor growth, metastasis, and therapeutic resistance in pancreatic cancer. In this study, we aimed to investigate the effect of juglone on cell proliferation in pancreatic cancer and to determine whether its potential effects occur via the IGF-IR/PI3K/p85 signaling pathway. The PANC-1 pancreatic cancer cell line was cultured and treated with juglone at concentrations of 5, 10, 15, and 20 µM for 24 hours. The expressions levels of IGF-IR and proliferating cell nuclear antigen (PCNA), an indicator of cell proliferation, as well as p85/PIK3R1 gene transcription, a major downstream molecule of the IGF-IR/PI3K pathway, were evaluated by immunofluorescence analysis and quantitative polymerase chain reaction (qPCR), respectively. Juglone significantly downregulated IGF-IR and PCNA expressions, as well as p85/PIK3R1 transcription in PANC-1 pancreatic cancer cells. These findings suggest that juglone exhibits a potent antiproliferative effect and has the potential to suppress various processes involving the IGF-IR/PI3K/p85 signaling pathway, including tumor growth, metastasis, therapeutic resistance, stemness, and the epithelial-mesenchymal transition (EMT) phenotype of cancer cells. Juglone exerts negative regulatory effects on pancreatic cancer, some of which are likely mediated through the IGF-IR/PI3K/p85 signaling pathway. Therefore, juglone may serve as a potential therapeutic option for the treatment and prevention of the progression of this devastating cancer.
Study Information
pubmed
2025
2025-03-24T00:00:00.000Z
10.14744/cpr.2025.50464
40